1483 related articles for article (PubMed ID: 19345298)
1. Frequency, indications, outcomes, and predictive factors of opioid switching in an acute palliative care unit.
Mercadante S; Ferrera P; Villari P; Casuccio A; Intravaia G; Mangione S
J Pain Symptom Manage; 2009 Apr; 37(4):632-41. PubMed ID: 19345298
[TBL] [Abstract][Full Text] [Related]
2. Rapid switching between transdermal fentanyl and methadone in cancer patients.
Mercadante S; Ferrera P; Villari P; Casuccio A
J Clin Oncol; 2005 Aug; 23(22):5229-34. PubMed ID: 16051965
[TBL] [Abstract][Full Text] [Related]
3. Opioid switching from transdermal fentanyl to oral methadone in patients with cancer pain.
Benítez-Rosario MA; Feria M; Salinas-Martín A; Martínez-Castillo LP; Martín-Ortega JJ
Cancer; 2004 Dec; 101(12):2866-73. PubMed ID: 15529307
[TBL] [Abstract][Full Text] [Related]
4. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
5. Sustained-release oral morphine versus transdermal fentanyl and oral methadone in cancer pain management.
Mercadante S; Porzio G; Ferrera P; Fulfaro F; Aielli F; Verna L; Villari P; Ficorella C; Gebbia V; Riina S; Casuccio A; Mangione S
Eur J Pain; 2008 Nov; 12(8):1040-6. PubMed ID: 18353696
[TBL] [Abstract][Full Text] [Related]
6. Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.
Sittl R; Likar R; Nautrup BP
Clin Ther; 2005 Feb; 27(2):225-37. PubMed ID: 15811486
[TBL] [Abstract][Full Text] [Related]
7. Morphine-methadone opioid rotation in cancer patients: analysis of dose ratio predicting factors.
Benítez-Rosario MA; Salinas-Martín A; Aguirre-Jaime A; Pérez-Méndez L; Feria M
J Pain Symptom Manage; 2009 Jun; 37(6):1061-8. PubMed ID: 19171458
[TBL] [Abstract][Full Text] [Related]
8. Opioid switch in palliative care, opioid choice by clinical need and opioid availability.
Müller-Busch HC; Lindena G; Tietze K; Woskanjan S
Eur J Pain; 2005 Oct; 9(5):571-9. PubMed ID: 16139186
[TBL] [Abstract][Full Text] [Related]
9. Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.
Mercadante S; Villari P; Ferrera P; Porzio G; Aielli F; Verna L; Casuccio A
J Pain Symptom Manage; 2006 Aug; 32(2):175-9. PubMed ID: 16877185
[TBL] [Abstract][Full Text] [Related]
10. Factors predicting requirement of high-dose transdermal fentanyl in opioid switching from oral morphine or oxycodone in patients with cancer pain.
Kanbayashi Y; Hosokawa T; Okamoto K; Fujimoto S; Konishi H; Otsuji E; Yoshikawa T; Takagi T; Miki T; Taniwaki M
Clin J Pain; 2011 Oct; 27(8):664-7. PubMed ID: 21471811
[TBL] [Abstract][Full Text] [Related]
11. Switching methadone: a 10-year experience of 345 patients in an acute palliative care unit.
Mercadante S
Pain Med; 2012 Mar; 13(3):399-404. PubMed ID: 22360828
[TBL] [Abstract][Full Text] [Related]
12. Opioid plasma concentrations during a switch from transdermal fentanyl to methadone.
Mercadante S; Villari P; Ferrera P; Casuccio A; Gambaro V
J Palliat Med; 2007 Apr; 10(2):338-44. PubMed ID: 17472504
[TBL] [Abstract][Full Text] [Related]
13. Outcomes after intravenous opioids in emergency patients: a prospective cohort analysis.
O'Connor AB; Zwemer FL; Hays DP; Feng C
Acad Emerg Med; 2009 Jun; 16(6):477-87. PubMed ID: 19426295
[TBL] [Abstract][Full Text] [Related]
14. Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.
Freye E; Anderson-Hillemacher A; Ritzdorf I; Levy JV
Pain Pract; 2007 Jun; 7(2):123-9. PubMed ID: 17559481
[TBL] [Abstract][Full Text] [Related]
15. Outcome of opioid switching 4 weeks after discharge from a palliative care unit.
Mercadante S; Ferrera P; Casuccio A
Curr Med Res Opin; 2011 Dec; 27(12):2357-60. PubMed ID: 22029619
[TBL] [Abstract][Full Text] [Related]
16. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: results of a retrospective cohort study.
Sittl R; Nuijten M; Nautrup BP
Clin Ther; 2005 Jul; 27(7):1022-31. PubMed ID: 16154481
[TBL] [Abstract][Full Text] [Related]
17. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?
Mercadante S; Villari P; Ferrera P; Casuccio A
Eur J Pain; 2006 Feb; 10(2):153-9. PubMed ID: 16310719
[TBL] [Abstract][Full Text] [Related]
18. A prospective study evaluating the response of patients with unrelieved cancer pain to parenteral opioids.
Enting RH; Oldenmenger WH; van der Rijt CC; Wilms EB; Elfrink EJ; Elswijk I; Sillevis Smitt PA
Cancer; 2002 Jun; 94(11):3049-56. PubMed ID: 12115396
[TBL] [Abstract][Full Text] [Related]
19. Safety and effectiveness of intravenous morphine for episodic (breakthrough) pain using a fixed ratio with the oral daily morphine dose.
Mercadante S; Villari P; Ferrera P; Bianchi M; Casuccio A
J Pain Symptom Manage; 2004 Apr; 27(4):352-9. PubMed ID: 15050663
[TBL] [Abstract][Full Text] [Related]
20. From codeine to transdermal fentanyl for cancer pain control: a safety and efficacy clinical trial.
Mystakidou K; Befon S; Kouskouni E; Gerolymatos K; Georgaki S; Tsilika E; Vlahos L
Anticancer Res; 2001; 21(3C):2225-30. PubMed ID: 11501851
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]